Journal
PHARMACEUTICALS
Volume 2, Issue 3, Pages 194-205Publisher
MDPI
DOI: 10.3390/ph2030194
Keywords
resveratrol; Alzheimer's disease; Parkinson's disease; SIRT1
Categories
Funding
- Ministerio de Educacion y Ciencia [SAF-2009-13093]
- Instituto de Salud Carlos III [PI080400]
- Generalitat de Catalunya [2009/SGR00853]
- Fundacio La Marato de TV3 [063230]
- Agencia Espanola de Cooperacion Internacional para el Desarrollo AECID [B/016995/08]
- 'Beatriu de Pinos' postdoctoral contract - 'Generalitat de Catalunya'
Ask authors/readers for more resources
The prevention of aging is one of the most fascinating areas in biomedicine. The first step in the development of effective drugs for aging prevention is a knowledge of the biochemical pathways responsible for the cellular aging process. In this context it seems clear that free radicals play a key role in the aging process. However, in recent years it has been demonstrated that the families of enzymes called sirtuins, specifically situin 1 (SIRT1), have an anti-aging action. Thus, the natural compound resveratrol is a natural compound that shows a very strong activation of SIRT1 and also shows antioxidant effects. By activating sirtuin 1, resveratrol modulates the activity of numerous proteins, including peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1 alpha), the FOXO family, Akt (protein kinase B) and NF kappa beta. In the present review, we suggest that resveratrol may constitute a potential drug for prevention of ageing and for the treatment of several diseases due to its antioxidant properties and sirtuin activation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available